ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics, today announces a new financing totaling €46.3 million ($52.6million) to progress the clinical development of its therapeutic […]
The role genetics and gut bacteria play in human health has long been a fruitful source of scientific enquiry, but new research marks a significant step forward in unraveling this complex relationship. Its findings could […]
An article has been published in Frontiers in Medicine: Regulatory Science section, which proposes a new set of recommendations for addressing the various regulatory and technical challenges when assessing the safety of Live Biotherapeutic Products […]
Metabolon, Inc., the global leader in metabolomics, and DNA Genotek, a subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), have collaborated to bring OMNImet™·GUT, the first device for in-home collection and ambient-temperature storage and shipping of […]
Two of the most important and largest microbiome studies ever undertaken in patients with chronic inflammatory bowel disease have been conducted by a team of researchers in Cork from APC Microbiome Ireland. The research, which […]
Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company, announced today an exclusive license agreement and research collaboration with Takeda Pharmaceutical Company Limited (Takeda) to develop novel microbiome therapeutics for the treatment of gastrointestinal (GI) disorders. The preclinical program […]
Chr. Hansen Holding A/S has today entered into an agreement with the owners of UAS Laboratories LLC (“UAS Labs”) to acquire 100% of the Wisconsin based B2B company specializing in clinically documented probiotics. The acquisition […]
Pendulum Therapeutics, a cutting-edge microbiome company dedicated to making people healthier through microbiome-targeted solutions, announced today the launch of Pendulum Glucose Control, the first and only medical probiotic clinically shown to lower A1C and blood sugar […]
Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, today announced that it intends to sell, subject to market and other […]
Obese mice with unhealthy lifestyles gain significantly less weight and avoid type 2 diabetes when they receive viruses transplanted from the stool of lean mice. These are the findings of a new University of Copenhagen […]
Intralytix, Inc. announced that it has received a multimillion-dollar grant (AI 148054) from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), for the clinical development of its bacteriophage therapy […]